Managing population immunity to reduce or eliminate the risks of circulation following the importation of polioviruses

Vaccine

Volumn 33, Issue 13, 2015, Pages 1568-1577

  Thompson, Kimberly M ^a,b   Kalkowska, Dominika A ^a,c   Duintjer Tebbens, Radboud J ^a  

^a Kid Risk Inc   (United States)

^b UNIVERSITY OF CENTRAL FLORIDA COLLEGE OF MEDICINE   (United States)

^c DELFT UNIVERSITY OF TECHNOLOGY   (Netherlands)

Author keywords

Eradication; Polio; Population immunity; Vaccine

Indexed keywords

ORAL POLIOMYELITIS VACCINE; POLIOMYELITIS VACCINE;

ARTICLE; HUMAN POLIOVIRUS 1; HUMAN POLIOVIRUS 2; IMMUNITY; IMMUNIZATION; ISRAEL; NETHERLANDS; POLIOMYELITIS; POLIOMYELITIS VIRUS; POPULATION IMMUNITY; PRIORITY JOURNAL; SEROTYPE; UNITED STATES; VACCINATION; VIRAL CLEARANCE; VIRUS TRANSMISSION; DISEASE ERADICATION; DISEASE MANAGEMENT; EPIDEMIC; HEALTH; HEALTH CARE PLANNING; HUMAN; IMMUNOLOGY; RISK; TRANSMISSION;

COMMUNITY HEALTH PLANNING; DISEASE ERADICATION; DISEASE MANAGEMENT; DISEASE OUTBREAKS; GLOBAL HEALTH; HUMANS; IMMUNITY; ISRAEL; NETHERLANDS; POLIOMYELITIS; POLIOVIRUS; POLIOVIRUS VACCINE, INACTIVATED; POLIOVIRUS VACCINE, ORAL; RISK; SEROGROUP; UNITED STATES; VACCINATION;

EID: 84925013309     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2015.02.013     Document Type: Article

References (37)

1. World Health Organization Global polio eradication initiative 2014.
2. Anis E., Kopel E., Singer S., Kaliner E., Moerman L., Moran-Gilad J., et al. Insidious reintroduction of wild poliovirus into Israel, 2013. Euro Surveill 2013, 18. (pii=20586).
3. Shulman L.M., Mendelson E., Anis E., Bassal R., Gdalevich M., Hindiyeh M., et al. Laboratory challenges in response to silent introduction and sustained transmission of wild type 1 poliovirus into Israel in 2013. J Infect Dis 2014, 210:S304-S314.
4. Kalkowska D.A., Duintjer Tebbens R.J., Grotto I., Shulman L.M., Anis E., Wassilak S.G.F., et al. Modeling options to manage type 1 wild poliovirus imported into Israel in 2013. J Infect Dis 2014, 2014. 0.1093/infdis/jiu674.
5. World Health Organization Poliovirus detected from environmental samples in Egypt 2013, WHO, Geneva, 11 February 2013 Available from http://wwwwhoint/csr/don/2013_02_11/en/Accessed 27 October 2014.
6. World Health Organization Temporary recommendations to reduce international spread of poliovirus 2014, WHO, Geneva, 5 May 2014 Available at: http://www.polioeradication.org/Infectedcountries/PolioEmergency.aspx, accessed 3 June 2014.
7. Thompson K.M., Pallansch M.A., Duintjer Tebbens R.J., Wassilak S.G.F., Cochi S.L. Modeling population immunity to support efforts to end the transmission of live polioviruses. Risk Anal 2013, 33:647-663.
8. Thompson K.M., Pallansch M.A., Duintjer Tebbens R.J., Wassilak S.G., Kim J-H., Cochi S.L. Pre-eradication vaccine policy options for poliovirus infection and disease control. Risk Anal 2013, 33:516-543.
9. Mach O., Tangermann R.H., Wassilak S.G.F., Singh S., Sutter R.W. Outbreaks of paralytic poliomyelitis during 1996-2012: the changing epidemiology of a disease in the final stages of eradication. J Infect Dis 2014, 210:S347-S352.
10. Duintjer Tebbens R.J., Pallansch M., Kew O., Cáceres V., Jafari H., Cochi S., et al. Risks of paralytic disease due to wild or vaccine-derived poliovirus after eradication. Risk Anal 2006, 26:1471-1505.
11. Duintjer Tebbens R.J., Pallansch M.A., Kim J.-H., Burns C.C., Kew O.M., Oberste M.S., et al. Oral poliovirus vaccine evolution and insights relevant to modeling the risks of circulating vaccine-derived polioviruses (cVDPVs). Risk Anal 2013, 23:680-702. (Review).
12. Duintjer Tebbens R.J., Pallansch M.A., Chumakov K.M., Halsey N.A., Hovi T., Minor P.D., et al. Expert review on poliovirus immunity and transmission. Risk Anal 2013, 33:544-605.
13. Duintjer Tebbens R.J., Pallansch M.A., Chumakov K.M., Halsey N.A., Hovi T., Minor P.D., et al. Review and assessment of poliovirus immunity and transmission: synthesis of knowledge gaps and identification of research needs. Risk Anal 2013, 33:606-646.
14. Duintjer Tebbens R.J., Pallansch M.A., Kew O.M., Cáceres V.M., Sutter R.W., Thompson K.M. A dynamic model of poliomyelitis outbreaks: learning from the past to help inform the future. Am J Epidemiol 2005, 162:358-372.
15. Duintjer Tebbens R.J., Pallansch M.A., Kalkowska D.A., Wassilak S.G., Cochi S.L., Thompson K.M. Characterizing poliovirus transmission and evolution: insights from modeling experiences with wild and vaccine-related polioviruses. Risk Anal 2013, 23:703-749.
16. Thompson K.M., Duintjer Tebbens R.J. Current polio global eradication and control policy options: perspectives from modeling and prerequisites for OPV cessation. Exp Rev Vaccines 2012, 11:449-459.
17. Thompson K.M., Duintjer Tebbens R.J. Modeling the dynamics of oral poliovirus vaccine cessation. J Infect Dis 2014, 210:475-484.
18. Duintjer Tebbens R.J., Thompson K.M. Modeling the potential role of inactivated poliovirus vaccine to manage the risks of oral poliovirus vaccine cessation. J Infect Dis 2014, 210:485-497.
19. Kalkowska D.A., Duintjer Tebbens R.J., Thompson K.M. Modeling strategies to increase population immunity and prevent poliovirus transmission in two high-risk areas in northern India. J Infect Dis 2014, 210:398-411.
20. Kalkowska D.A., Duintjer Tebbens R.J., Thompson K.M. Modeling strategies to increase population immunity and prevent poliovirus transmission in the high-risk area of northwest Nigeria. J Infect Dis 2014, 210:412-423.
21. World Health Organization Global polio eradication initiative: polio eradication and endgame strategic plan (2013-2018) 2013, World Health Organization, Geneva.
22. Thompson K.M., Wallace G.S., Duintjer Tebbens R.J., Smith P.H., Barskey A.E., Pallansch M.A., et al. Trends in the risk of U.S. polio outbreaks and poliovirus vaccine availability for response. Public Health Rep 2012, 127:23-37.
23. Duintjer Tebbens R.J., Kalkowska D.A., Wassilak S.G., Pallansch M.A., Cochi S.L., Thompson K.M. The potential impact of expanding target age groups for polio immunization campaigns. BMC Infect Dis 2014, 14:45.
24. Kalkowska D.A., Duintjer Tebbens R.J., Pallansch M.A., Cochi S.L., Wassilak S.G.F., Thompson K.M. Modeling undetected live poliovirus circulation after apparent interruption of transmission: implications for surveillance and vaccination. BMC Infect Dis 2015, 15:66.
25. Kisjes K.H., Duintjer Tebbens R.J., Wallace G.S., Pallansch M.A., Cochi S.L., Wassilak S.G.F., et al. Individual-based modeling of potential poliovirus transmission in connected religious communities in North America with low uptake of vaccination. J Infect Dis 2014, 210:424-433.
26. Shulman L.M., Martin J., Sofer D., Burns C.C., Manor Y., Hindiyeh M., et al. Genetic analysis and characterization of wild poliovirus type 1 during sustained transmission in a population with >95% vaccine coverage, Israel 2013. Clin Infect Dis 2014, 10.1093/cid/ciu1136.
27. van Lier E.A., Oomen P.J., Mulder M., Conyn-van Spaendonck M.A.E., Drijfhout I.H., de Hoogh P.A.A.M., et al. Vaccinatiegraad Rijksvaccinatieprogramma Nederland: Verslagjaar 2013 (in Dutch). RIVM rapport 150202001 2013, Rijksinstituut voor Volksgezondheid en Milieu.
28. Schaap G.J.P., Bijkerk H., Coutinho R.A., Kapsenberg J.G., Vanwezel A.L. The spread of wild poliovirus in the well-vaccinated Netherlands in connection with the 1978 epidemic. Prog Med Virol 1984, 29:124-140.
29. Oostvogel P.M., Rumke H.C., Conyn-Van Spaendonck M.A., van der Avoort H.G., Leeuwenburg J., van Loon A.M. Poliovirus circulation among schoolchildren during the early phase of the 1992-1993 poliomyelitis outbreak in The Netherlands. J Infect Dis 2001, 184:1451-1455.
30. Knol M., Urbanus A., Swart E., Mollem L., Ruijs W., van Binnendijk R., et al. Large ongoing measles outbreak in a religious community in the Netherlands since May 2013. Euro Surveill 2013, 18. (pii=20580).
31. Ruijs W.L., Hautvast J.L., van der Velden K., de Vos S., Knippenberg H., Hulscher M.E. Religious subgroups influencing vaccination coverage in the Dutch Bible belt: an ecological study. BMC Public Health 2011, 11:102.
32. Thompson K.M., Duintjer Tebbens R.J. Retrospective cost-effectiveness analyses for polio vaccination in the United States. Risk Anal 2006, 26:1423-1440.
33. Oostvogel P., van Wijngaarden J., van der Avoort H.G., Mulders M.N., Conyn-van Spaendonck M.A., Rümke H., et al. Poliomyelitis outbreak in an unvaccinated community in the Netherlands, 1992-3. Lancet 1994, 344:665-670.
34. Thompson K.M., Duintjer Tebbens R.J. The case for cooperation in managing and maintaining the end of poliomyelitis: stockpile needs and coordinated OPV cessation. Medscape J Med 2008, 10:190.
35. Jenkins P.C., Modlin J.F. Decision analysis in planning for a polio outbreak in the United States. Pediatrics 2006, 118:611-618.
36. Thompson K.M., Duintjer Tebbens R.J. National choices related to inactivated poliovirus vaccine, innovation, and the end game of global polio eradication. Exp Rev Vaccines 2014, 13:221-234.
37. Alexander L.N., Seward J.F., Santibanez T.A., Pallansch M.A., Kew O.M., Prevots D.R., et al. Vaccine policy changes and epidemiology of poliomyelitis in the United States. J Am Med Assoc 2004, 292:1696-1701.